|
1.
|
Ferlay J, Shin H-R, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar
|
|
3.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
4.
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, Kosary CL, et al: SEER Cancer Statistics
Review. 1975–2010, National Cancer Institute; Bethesda, MD:
http://seer.cancer.gov/csr/1975_2010/,
based on November 2012 SEER data submission, posted to the SEER web
site, 2013.
|
|
5.
|
Folkman J: Tumor angiogenesis. Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Conway E-M, Collen D and Carmeliet P:
Molecular mechanisms of blood vessel growth. Cardiovasc Res.
49:507–521. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chavakis E and Dimmeler S: Regulation of
endothelial cell survival and apoptosis during angiogenesis.
Arterioscler Thromb Vasc Biol. 22:887–893. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Van der Bilt AR, de Vries EG, de Jong S,
Timmer-Bosscha H, van der Zee AG and Reyners AK: Turning promise
into progress for antiangiogenic agents in epithelial ovarian
cancer. Crit Rev Oncol Hematol. 84:224–242. 2012.PubMed/NCBI
|
|
9.
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kaplan RN, Riba RD, Zacharoulis S, Bramley
AH, Vinent L, Costa C, MacDonald DD, et al: VEGFR1-positive
haematopoietic bone marrow progenitors initiate the pre-metastatic
niche. Nature. 6:820–827. 2005. View Article : Google Scholar
|
|
13.
|
Lichtenberger BM, Tan PK, Niederleithner
H, Ferrara N, Petzelbauer P and Sibilia M: Autocrine VEGF signaling
synergizes with EGFR in tumor cells to promote epithelial cancer
development. Cell. 6:268–279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Trinh XB, Tjalma WA, Vermeulen PB, Van den
Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, et al: The
VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human
epithelial ovarian cancer. Br J Cancer. 100:971–978. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Zhang A, Meng L, Wang Q, Chen G, Wang S,
Zhou J, Lu Y, et al: Enhanced in vitro invasiveness of
ovarian cancer cells through up-regulation of VEGF and induction of
MMP-2. Oncol Rep. 15:831–836. 2006.
|
|
16.
|
Artini PG, Ruggiero M, Monteleone P, Carpi
A, Cristello F, Cela V, Genazzani AR, et al: Vascular endothelial
growth factor and its soluble receptor in benign and malignant
ovarian tumors. Biomed Pharmacother. 62:373–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Lawicki S, Będkowska GE, Gacuta-Szumarska
E and Szmitkowski M: The plasma concentration of VEGF, HE4 and
CA125 as a new biomarkers panel in different stages and sub-types
of epithelial ovarian tumors. J Ovarian Res. 6:452013. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Lu KH, Patterson AP, Wang L, Marquez RT,
Atkinson EN, Baggerly KA, Ramoth LR, et al: Selection of potential
markers for epithelial ovarian cancer with gene expression arrays
and recursive descent partition analysis. Clin Cancer Res.
10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Li L, Wang L, Zhang W, Tang B, Zhang J,
Song H, Yao D, et al: Correlation of serum VEGF levels with
clinical stage, therapy efficacy, tumor metastasis and patient
survival in ovarian cancer. Anticancer Res. 24:1973–1979.
2004.PubMed/NCBI
|
|
20.
|
Rudlowski C, Pickart AK, Fuhljahn C,
Friepoertner T, Schlehe B, Biesterfeld S and Schroeder W:
Prognostic significance of vascular endothelial growth factor
expression in ovarian cancer patients: a long-term follow-up. Int J
Gynecol Cancer. 16:183–189. 2006. View Article : Google Scholar
|
|
21.
|
Yu L, Deng L, Li J, Zhang Y and Hu L: The
prognostic value of vascular endothelial growth factor in ovarian
cancer: a systematic review and meta-analysis. Gynecol Oncol.
128:391–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hu L, Hoffmann J, Zaloudak C, Ferrara N,
Hamilton T and Jaffe RB: Vascular endothelial growth factor
immunoneutralization plus paclitaxel markedly reduces tumor burden
and ascites in athymic mouse model of ovarian cancer. Am J Pathol.
161:1917–1924. 2002. View Article : Google Scholar
|
|
23.
|
Byrne AT, Ross L, Holash J, Nakanishi M,
Hu L, Hofmann JI, Yancopoulos GD, et al: Vascular endothelial
growth factor-trap decreases tumor burden, inhibits ascites, and
causes dramatic vascular remodeling in an ovarian cancer model.
Clin Cancer Res. 9:5721–5728. 2003.
|
|
24.
|
Tran J, Master Z, Yu JL, Rak J, Dumont DJ
and Kerbel RS: A role of surviving in chemoresistance of
endothelial cells mediated by VEGF. Proc Natl Acad Sci USA.
99:4349–4354. 2002. View Article : Google Scholar
|
|
25.
|
Martin L and Schilder R: Novel approaches
in advancing the treatment of epithelial ovarian cancer: the role
of angiogenesis inhibition. J Clin Oncol. 25:2894–2901. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Osada R, Horiuchi A, Kikuchi N, Ohira S,
Ota M, Katsuyama Y and Konishi I: Expression of semaphorins,
vascular endothelial growth factor, and their common receptor
neuropilins and alleic loss of semaphorin locus in epithelial
ovarian neoplasms: increased ratio of vascular endothelial growth
factor to semaphorin is a poor prognostic factor in ovarian
carcinomas. Hum Pathol. 37:1414–1425. 2006.
|
|
27.
|
Fu Y, Lai Y, Wang Q, Liu X, He W, Zhang H,
Fan C, et al: Overexpression of clusterin promotes angiogenesis via
the vascular endothelial growth factor in primary ovarian cancer.
Mol Med Rep. 7:1726–1732. 2013.PubMed/NCBI
|
|
28.
|
Eckhoff K, Flurschütz R, Trillsch F,
Mahner S, Jänicke F and Milde-Langosch K: The prognostic
significance of Jun transcription factors in ovarian cancer. J
Cancer Res Clin Oncol. 139:1673–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Mahner S, Baasch C, Schwarz J, Hein S,
Wölber L, Jänicke F and Milde-Langosch K: C-Fos expression is a
molecular predictor of progression and survival in epithelial
ovarian carcinoma. Br J Cancer. 99:1269–1275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kusumbe AP, Mali AM and Bapat SA:
CD133-expressing stem cells associated with ovarian metastases
establish an endothelial hierarchy and contribute to tumor
vasculature. Stem Cells. 27:498–508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kryczek I, Liu S, Roh M, Vatan L, Szeliga
W, Wei S, et al: Expression of aldehyde dehydrogenase and CD133
defines ovarian cancer stem cells. Int J Cancer. 130:29–39. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Burgos-Ojeda D, Rueda BR and Buckanovich
RJ: Ovarian cancer stem cell markers: Prognostic and therapeutic
implications. Cancer Lett. 322:1–7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Alvero AB, Fu HH, Holmberg J, Visintin I,
Mor L, Marquina CC, Oldtman J, et al: Stem-like ovarian cancer
cells can serve as tumor vascular progenitors. Stem Cells.
27:2405–2413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Liang D, Ma Y, Liu J, Trope CG, Holm R,
Nesland JM and Suo Z: The hypoxic microenvironment upgrades
stem-like properties of ovarian cancer cells. BMC Cancer.
12:2012012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Heddleston JM, Li Z, Lathia JD, Bao S,
Hjelmeland AB and Rich JN: Hypoxia inducible factors in cancer stem
cells. Br J Cancer. 102:789–795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Yin G, Alvero AB, Craveiro V, Holmberg JC,
Fu HH, Montagna MK, Yang Y, et al: Constitutive proteasomal
degradation of TWIST-1 in epithelial-ovarian cancer stem cells
impacts differentiation and metastatic potential. Oncogene.
32:39–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Cao L, Shao M, Schilder J, Guise T,
Mohammad KS and Matei D: Tissue transglutaminase links TGF-beta,
epithelial to mesenchymal transition and a stem cell phenotype in
ovarian cancer. Oncogene. 31:2521–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Jiao J, Huang L, Ye F, Shi M, Cheng X,
Wang X, Hu D, et al: Cyclin D1 affects epithelial-mesenchymal
transition in epithelial ovarian cancer stem cell-like cells. Onco
Targets Ther. 6:667–677. 2013.
|
|
39.
|
Yang H and Chen B: CD147 in ovarian and
other cancers. Int J Gynecol Cancer. 23:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Yang H, Zou W and Chen B: Overexpression
of CD147 in ovarian cancer is initiated by the hypoxic
microenvironment. Cell Biol Int. 37:1139–1142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Millimaggi D, Mari M, D’Ascenzo S, Carosa
E, Jannini EA, Zucker S, Carta G, et al: Tumor vesicle-associated
CD147 modulates the angiogenic capability of endothelial cells.
Neoplasia. 9:349–357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Zaffryar-Eilot S, Marshall D, Voloshin T,
Bar-Zion A, Spangler R, Kessler O, Ghermazien H, et al: Lysyl
oxidase-like-2 promotes tumour angiogenesis and is a potential
therapeutic target in angiogenic tumours. Carcinogenesis.
34:2370–2379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S
and Fu S: Id1 enhances human ovarian cancer endothelial progenitor
cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways.
J Transl Med. 11:1322013.PubMed/NCBI
|
|
44.
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW, et al: MicroRNA expression profiles in serous ovarian
carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar
|
|
45.
|
He J, Jing Y, Li W, Qian X, Xu Q, Li FS,
Liu LZ, et al: Roles and mechanism of miR-199a and miR-125b in
tumor angiogenesis. PLoS One. 8:e566472013. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Bamias A, Pignata S and Pujade-Lauraine E:
Angiogenesis: A promising therapeutic target for ovarian cancer.
Crit Rev Oncol Hematol. 84:314–326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Ziogas, Gavalas N, Tsiatas M, Tsitsilonis
O, Politi E, Terpos E, Rodolakis A, et al: VEGF directly suppresses
activation of T cells from ovarian cancer patients and healthy
individuals via VEGF receptor type 2. Int J Cancer. 130:857–864.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Wang X, Zhao X, Wang K, Wu L and Duan T:
Interaction of monocytes/macrophages with ovarian cancer cells
promotes angiogenesis in vitro. Cancer Sci. 104:516–523. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Lin YS, Nguyen C, Mendoza JL, Escandon E,
Fei D, Meng YG and Modi NB: Preclinical pharmacokinetics,
interspecies scaling, and tissue distribution of a humanized
monoclonal antibody against vascular endothelial growth factor. J
Pharmacol Exp Ther. 288:371–378. 1999.
|
|
50.
|
Jain R: Antiangiogenic therapy for cancer:
current and emerging concepts. Oncology (Williston Park). 19:7–16.
2005.PubMed/NCBI
|
|
51.
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, et al: Incorporation of
bevacizumab in the primary treatment of ovarian cancer. N Engl J
Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade- Lauraine E, Kristensen G, Carey MS, et al: A
phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med.
365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Aghajanian C, Blank SV, Goff BA, Judson
PL, Teneriello MG, Husain A, Sovak MA, et al: OCEANS: a randomized,
double-blind, placebo-controlled phase III trial of chemotherapy
with or without bevacizumab in patients with platinum-sensitive
recurrent epithelial ovarian, primary peritoneal, or fallopian tube
cancer. J Clin Oncol. 30:2039–2045. 2012. View Article : Google Scholar
|
|
54.
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, et al: AURELIA: a
randomised phase III trial evaluating bevacizumab combined with
chemotherapy for platinum resistant recurrent ovarian cancer. J
Clin Oncol. 30:(abst, LBA5002),. 2012.
|
|
55.
|
Garcia A, Hirte H, Fleming G, Yang D,
Tsao- Wei D, Roman L, Groshen S, et al: Phase II clinical trial of
bevacizumab and low-dose metronomic oral cyclophosphamide in
recurrent ovarian cancer: a trial of the California, Chicago, and
Princess Margaret Hospital phase II consortia. J Clin Oncol.
26:76–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
McGonigle K, Muntz H, Vuky J, Paley P,
Veljovich D, Greer B, Goff BA, et al: Combined weekly topotecan and
biweekly bevacizumab in women with platinum-resistant ovarian,
peritoneal, or fallopian tube cancer: results of a phase 2 study.
Cancer. 117:3731–3740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Kudoh K, Takano M, Kouta H, Kikuchi R,
Kita T, Miyamoto M, Watanabe A, et al: Effects of bevacizumab and
pegylated liposomal doxorubicin for the patients with recurrent or
refractory ovarian cancers. Gynecol Oncol. 122:233–237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
O’Malley DM, Richardson DL, Rheaume PS,
Salani R, Eisenhauer EL, McCann GA, Fowler JM, et al: Addition of
bevacizumab to weekly paclitaxel significantly improves
progression-free survival in heavily pretreated recurrent
epithelial ovarian cancer. Gynecol Oncol. 121:269–272. 2011.
|
|
59.
|
Verschraegen CF, Czok S, Muller CY, Boyd
L, Lee SJ, Rutledge T, Blank S, et al: Phase II study of
bevacizumab with liposomal doxorubicin for patients with platinum-
and taxane-resistant ovarian cancer. Ann Oncol. 23:3104–3110. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Tillmanns TD, Lowe MP, Walker MS,
Stepanski EJ and Schwartzberg LS: Phase II clinical trial of
bevacizumab with albumin-bound paclitaxel in patients with
recurrent, platinum-resistant primary epithelial ovarian or primary
peritoneal carcinoma. Gynecol Oncol. 128:221–228. 2013. View Article : Google Scholar
|
|
61.
|
Del Carmen MG, Micha J, Small L, Street
DG, Londhe A and McGowan T: A phase II clinical trial of pegylated
liposomal doxorubicin and carboplatin plus bevacizumab in patients
with platinum-sensitive recurrent ovarian, fallopian tube, or
primary peritoneal cancer. Gynecol Oncol. 126:369–374. 2012.
|
|
62.
|
Burger R, Sill M, Monk B, Greer B and
Sorosky J: Phase II trial of bevacizumab in persistent or recurrent
epithelial ovarian cancer or primary peritoneal cancer: a
Gynecologic Oncology Group study. J Clin Oncol. 25:5165–5171. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Cannistra S, Matulonis U, Penson R,
Hambleton J, Dupont J, Mackey H, Douglas J, et al: Phase II study
of bevacizumab in patients with platinum-resistant ovarian cancer
or peritoneal serous cancer. J Clin Oncol. 25:5180–5186. 2007.
View Article : Google Scholar
|
|
64.
|
Nimeiri HS, Oza AM, Morgan RJ, Friberg G,
Kasza K, Faoro L, Salgia R, et al: Efficacy and safety of
bevacizumab plus erlotinib for patients with recurrent ovarian,
primary peritoneal, and fallopian tube cancer: a trial of the
Chicago, PMH, and California Phase II Consortia. Gynecol Oncol.
110:49–55. 2008. View Article : Google Scholar
|
|
65.
|
Chambers SK, Clouser MC, Baker AF, Roe DJ,
Cui H, Brewer MA, Hatch KD, et al: Overexpression of tumor vascular
endothelial growth factor A may portend an increased likelihood of
progression in a phase II trial of bevacizumab and erlotinib in
resistant ovarian cancer. Clin Cancer Res. 16:5320–5328. 2010.
View Article : Google Scholar
|
|
66.
|
Morgan R, Oza AM, Qin R, Laumann KM,
Mackay H, Strevel EL, Welch S, et al: A phase II trial of
temsirolimus and bevacizumab in patients with endometrial, ovarian,
hepatocellular carcinoma, carcinoid, or islet cell cancer: ovarian
cancer (OC) subset - a study of the Princess Margaret, Mayo,
Southeast phase II, and California Cancer (CCCP) N01 Consortia
NCI#8233. J Clin Oncol. 29:50152011.
|
|
67.
|
Kohn EC, Lee J, Annunziata CM, Minasian
LM, Zujewski J, Prindiville SA, Kotz HL, et al: A phase II study of
intermittent sorafenib with bevacizumab in bevacizumab-naive
epithelial ovarian cancer (EOC) patients. J Clin Oncol.
29:50192011.
|
|
68.
|
Tew WP, Colombo N, Ray-Coquard I, Oza A,
del Campo J, Scambia G and Spriggs D: VEGF-Trap for patients (pts)
with recurrent platinum-resistant epithelial ovarian cancer (EOC):
Preliminary results of a randomized, multicenter phase II study. J
Clin Oncol. 25:55082007.
|
|
69.
|
Colombo N, Mangili G, Mammoliti S, Kalling
M, Tholander B, Sternas L, Buzenet G, et al: A phase II study of
aflibercept in patients with advanced epithelial ovarian cancer and
symptomatic malignant ascites. Gynecol Oncol. 125:42–47. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Friedlander M, Hancock KC, Rischin D, Ma
B, et al: A phase II open-label study evaluating pazopanib in
patients with recurrent ovarian cancer. Gynecol Oncol. 119:32–37.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Matulonis UA, Berlin S, Ivy P, Tyburski K,
Krasner C, Zarwan C, Berkenblit A, et al: Cediranib, an oral
inhibitor of vascular endothelial growth factor receptor kinases,
is an active drug in recurrent epithelial ovarian, fallopian tube,
and peritoneal cancer. J Clin Oncol. 27:5601–5606. 2009. View Article : Google Scholar
|
|
72.
|
Biagi JJ, Oza AM, ChalCha HI, Grimshaw R,
Ellard SL, Lee U, Hirte H, et al: A phase II study of sunitinib in
patients with recurrent epithelial ovarian and primary peritoneal
carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol.
22:335–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Matei D, Sill MW, Lankes HA, DeGeest K,
Bristow RE, Mutch D, Yamada SD, et al: Activity of sorafenib in
recurrent ovarian cancer and primary peritoneal carcinomatosis: a
gynecologic oncology group trial. J Clin Oncol. 29:69–75. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Welch SA, Hirte WHMD, Elit L, Schilder RJ,
Wang L, Macalpine K, Wright JJ, et al: Sorafenib in combination
with gemcitabine in recurrent epithelial ovarian cancer. A study of
the Princess Margaret Hospital Phase II Consortium. Int J Gynecol
Cancer. 20:787–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75.
|
Pölcher M, Eckhardt M, Coch C, Wolfgarten
M, Kübler K, Hartmann G, Kuhn W, et al: Sorafenib in combination
with carboplatin and paclitaxel as neoadjuvant chemotherapy in
patients with advanced ovarian cancer. Cancer Chemother Pharmacol.
66:203–207. 2010.PubMed/NCBI
|
|
76.
|
Matei D, Ramasubbaiah R, Schilder J,
Perkins S, Whalen C, Breen T, Johnson CS, et al: A phase I/II study
of topotecan and sorafenib in recurrent, platinum-resistant ovarian
cancer: HOG GYN-111. J Clin Oncol. 28:51082010.
|
|
77.
|
Ledermann JA, Hackshaw A, Kaye S, Jayson
G, Gabra H, McNeish I, Earl H, et al: Randomized phase II
placebo-controlled trial of maintenance therapy using the oral
triple angiokinase inhibitor BIBF 1120 after chemotherapy for
relapsed ovarian cancer. J Clin Oncol. 29:3798–3804. 2011.
View Article : Google Scholar
|
|
78.
|
Buckanovich RJ, Berger R, Sella A, Sikic
BI, Shen X, Ramies DA, Smith DC, et al: Activity of cabozantinib
(XL184) in advanced ovarian cancer patients (pts): results from a
phase II randomized discontinuation trial (RDT). J Clin Oncol.
29:50082011.
|
|
79.
|
Schilder RJ, Sill MW, Lee RB, Shaw TJ,
Senterman MK, Klein-Szanto AJ, Miner Z, et al: Phase II evaluation
of imatinib mesylate in the treatment of recurrent or persistent
epithelial ovarian or primary peritoneal carcinoma: a gynecologic
oncology group study. J Clin Oncol. 26:3418–3425. 2008. View Article : Google Scholar
|
|
80.
|
Karlan BY, Oza AM, Richardson GE,
Provencher DM, Hansen VL, Buck M, Chambers SK, et al: Randomized,
double-blind, placebo-controlled phase II study of AMG 386 combined
with weekly paclitaxel in patients with recurrent ovarian cancer. J
Clin Oncol. 30:362–371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81.
|
Downs LS Jr, Judson PL, Argenta PA, Ghebre
R, Geller MA, Bliss RL, Boente MP, et al: A prospective randomized
trial of thalidomide with topotecan compared with topotecan alone
in women with recurrent epithelial ovarian carcinoma. Cancer.
112:331–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
82.
|
Hurteau JA, Brady MF, Darcy KM, McGuire
WP, Edmonds P, Pearl ML, Ivanov I, et al: Randomized phase III
trial of tamoxifen versus thalidomide in women with
biochemical-recurrent-only epithelial ovarian, fallopian tube or
primary peritoneal carcinoma after a complete response to
first-line platinum/taxane chemotherapy with an evaluation of serum
vascular endothelial growth factor (VEGF): A Gynecologic Oncology
Group Study. Gynecol Oncol. 119:444–450. 2010.
|
|
83.
|
Bell-McGuinn KM, Matthews CM, Ho SN, Barve
M, Gilbert L, Penson RT, LengYel E, et al: A phase II, single-arm
study of the anti-α5β1 integrin antibody volociximab as monotherapy
in patients with platinum-resistant advanced epithelial ovarian or
primary peritoneal cancer. Gynecol Oncol. 121:273–279. 2011.
|
